These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19243793)

  • 21. [Pharmacological sheet: eplerenone (Inspra), orally].
    J Pharm Belg; 2011 Sep; (3):93-4. PubMed ID: 21995102
    [No Abstract]   [Full Text] [Related]  

  • 22. The use of aldosterone receptor blockers in the treatment of hypertension.
    Weinberger MH
    J Clin Hypertens (Greenwich); 2004 Nov; 6(11):632-5. PubMed ID: 15538096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacology profile and clinical findings of Selara Tablets (eplerenone)].
    Nomura S; Tabira J; Hayashi T; Hamada Y
    Nihon Yakurigaku Zasshi; 2008 Oct; 132(4):227-35. PubMed ID: 18854625
    [No Abstract]   [Full Text] [Related]  

  • 24. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Aldosterone antagonists--first choice in resistant hypertension].
    Holzgreve H
    MMW Fortschr Med; 2016 Apr; 158(7):65-6. PubMed ID: 27071591
    [No Abstract]   [Full Text] [Related]  

  • 27. Eplerenone, amlodipine and experimental hypertension: one plus one equals three.
    Funder JW
    Hypertens Res; 2011 Jul; 34(7):795-6. PubMed ID: 21614006
    [No Abstract]   [Full Text] [Related]  

  • 28. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.
    Pechère-Bertschi A; Herpin D; Lefebvre H
    Ann Endocrinol (Paris); 2016 Jul; 77(3):226-34. PubMed ID: 27315759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eplerenone for the treatment of cardiovascular disorders.
    Watanabe M; Krum H
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of eplerenone versus losartan in patients with low-renin hypertension.
    Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL
    Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertension and ethnic group: eplerenone may have role in hypertension related atrial fibrillation.
    Jolobe OM
    BMJ; 2006 Apr; 332(7547):974. PubMed ID: 16627524
    [No Abstract]   [Full Text] [Related]  

  • 32. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
    MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
    [No Abstract]   [Full Text] [Related]  

  • 33. Adrenal gland inclusions in patients treated with aldosterone antagonists (Spironolactone/Eplerenone): incidence, morphology, and ultrastructural findings.
    Patel KA; Calomeni EP; Nadasdy T; Zynger DL
    Diagn Pathol; 2014 Aug; 9():147. PubMed ID: 25108298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.
    Takeda Y
    Hypertens Res; 2009 May; 32(5):321-4. PubMed ID: 19300447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension.
    Jansen PM; Frenkel WJ; van den Born BJ; de Bruijne EL; Deinum J; Kerstens MN; Arnoldus JH; Woittiez AJ; Wijbenga JA; Zietse R; Danser AH; van den Meiracker AH
    J Hypertens; 2013 Feb; 31(2):404-13. PubMed ID: 23249826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eplerenone (GD Searle & Co).
    Martin J; Krum H
    Curr Opin Investig Drugs; 2001 Apr; 2(4):521-4. PubMed ID: 11566010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Eplerenone Post-AMI Heart Failure Efficacy and survival study (EPHESUS)].
    Takata Y; Asano K; Yamashina A
    Nihon Rinsho; 2005 Mar; 63 Suppl 3():336-41. PubMed ID: 15813091
    [No Abstract]   [Full Text] [Related]  

  • 38. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
    Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB
    Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of eplerenone on nephrotic syndrome in a patient with renovascular hypertension.
    Suzuki J; Otsuka F; Inagaki K; Tanabe K; Tsukamoto N; Miyoshi T; Nakamura E; Ogura T; Kumagai I; Makino H
    Hypertens Res; 2011 Mar; 34(3):404-6. PubMed ID: 21160478
    [No Abstract]   [Full Text] [Related]  

  • 40. Aldosterone receptor antagonists in the treatment of heart failure.
    Perkerson KA; Coleman CI; White CM
    Conn Med; 2003 Aug; 67(7):397-400. PubMed ID: 14502862
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.